chlorpromazine has been researched along with remoxipride in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chouinard, G | 1 |
| Angeby, K; Florvall, L; Hall, H; Köhler, C; Lindbom, LO; Magnusson, O; Ogren, SO | 1 |
| King, DJ | 1 |
| Basta-Kaim, A; Budziszewska, B; Jaworska-Feil, L; Kubera, M; Lasoń, W; Leśkiewicz, M; Tetich, M | 1 |
| Bastianetto, S; Danik, M; Mennicken, F; Quirion, R; Williams, S | 1 |
1 review(s) available for chlorpromazine and remoxipride
| Article | Year |
|---|---|
Psychomotor impairment and cognitive disturbances induced by neuroleptics.
Topics: Antipsychotic Agents; Attention; Chlorpromazine; Cognition Disorders; Eye Movements; Humans; Neurologic Examination; Neuropsychological Tests; Psychomotor Disorders; Remoxipride; Schizophrenia; Schizophrenic Psychology | 1994 |
1 trial(s) available for chlorpromazine and remoxipride
| Article | Year |
|---|---|
A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Chlorpromazine; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Remoxipride; Schizophrenia; Schizophrenic Psychology | 1990 |
13 other study(ies) available for chlorpromazine and remoxipride
| Article | Year |
|---|---|
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Topics: Animals; Biometry; Dogs; Drug Evaluation, Preclinical; Haloperidol; Haplorhini; Humans; Injections, Intravenous; Liver; Liver Circulation; Metabolic Clearance Rate; Mifepristone; Molecular Structure; Molecular Weight; Rats; Reproducibility of Results | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Binding, Competitive; Brain Chemistry; Catalepsy; Chlorpromazine; Dogs; Female; Haloperidol; Histocytochemistry; Humans; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Remoxipride; Spiperone; Sulpiride; Thioridazine; Vomiting | 1984 |
Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium-dependent manner.
Topics: Animals; Antipsychotic Agents; Calcimycin; Calcium; Calcium Channel Blockers; Cell Line; Cell Line, Transformed; Chloramphenicol O-Acetyltransferase; Chlorpromazine; Clozapine; Colforsin; Cyclic AMP; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Estrenes; Fibroblasts; Gene Expression Regulation; Genes, Reporter; Haloperidol; Histamine; Histamine H1 Antagonists; Ionophores; Mammary Tumor Virus, Mouse; Mice; Nifedipine; Phorbol Esters; Phosphodiesterase Inhibitors; Protein Kinase C; Protein Kinase C-alpha; Pyrilamine; Pyrrolidinones; Raclopride; Receptors, Glucocorticoid; Remoxipride; Sulfonamides; Sulpiride; Tetradecanoylphorbol Acetate; Thionucleotides; Transcription, Genetic; Type C Phospholipases | 2002 |
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Topics: Animals; Anisoles; Antipsychotic Agents; Benzazepines; Butaclamol; Caspase Inhibitors; Cell Death; Cells, Cultured; Chlorpromazine; Clozapine; Domperidone; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Ginkgo biloba; Haloperidol; Hippocampus; Indans; Isoxazoles; Neurons; Neuroprotective Agents; Peptides; Piperidines; Plant Extracts; Propylamines; Raclopride; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Remoxipride; Risperidone; Sulpiride | 2006 |